Loading...
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
INTRODUCTION: Limited comparative effectiveness data for rituximab (RTX) versus natalizumab (NTZ), fingolimod (FTY), and dimethyl fumarate (DMF) for the treatment of multiple sclerosis (MS) exist. METHODS: Clinician‐reported data on patients prescribed RTX, NTZ, FTY, or DMF for the treatment of MS a...
Na minha lista:
| Udgivet i: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7480919/ https://ncbi.nlm.nih.gov/pubmed/32767538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51111 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|